stoxline Quote Chart Rank Option Currency Glossary
Arbutus Biopharma Corporation (ABUS)
2.98  0.09 (3.11%)    05-17 16:00
Open: 2.93
High: 3.01
Volume: 745,396
Pre. Close: 2.89
Low: 2.89
Market Cap: 562(M)
Technical analysis
2024-05-17 4:43:43 PM
Short term     
Mid term     
Targets 6-month :  3.51 1-year :  4.1
Resists First :  3 Second :  3.51
Pivot price 2.82
Supports First :  2.77 Second :  2.63
MAs MA(5) :  2.88 MA(20) :  2.79
MA(100) :  2.67 MA(250) :  2.32
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  75.1 D(3) :  70.1
RSI RSI(14): 61.4
52-week High :  3.28 Low :  1.69
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ ABUS ] has closed below upper band by 4.6%. Bollinger Bands are 27.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.01 - 3.02 3.02 - 3.04
Low: 2.86 - 2.87 2.87 - 2.89
Close: 2.96 - 2.98 2.98 - 3
Company Description

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Headline News

Fri, 17 May 2024
Whitefort Urges Arbutus Biopharma To Strike Deals, Not Dilute Shares - Finimize

Fri, 17 May 2024
Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value - Chronicle-Tribune

Wed, 15 May 2024
Short Interest in Arbutus Biopharma Co. (NASDAQ:ABUS) Grows By 12.4% - MarketBeat

Wed, 15 May 2024
Arbutus Biopharma Co. (NASDAQ:ABUS) Short Interest Up 12.4% in April - Defense World

Sun, 12 May 2024
Why Arbutus (ABUS) Stock Might be a Great Pick - Yahoo New Zealand News

Fri, 03 May 2024
Arbutus Biopharma First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Simply Wall St

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 189 (M)
Held by Insiders 1.3383e+008 (%)
Held by Institutions 22.2 (%)
Shares Short 4,550 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -7.865e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -1 %
Return on Assets (ttm) 252.1 %
Return on Equity (ttm) -29.4 %
Qtrly Rev. Growth 1.299e+007 %
Gross Profit (p.s.) -37.61
Sales Per Share -28.07
EBITDA (p.s.) 0
Qtrly Earnings Growth -0.5 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -78 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.11
Price to Cash Flow 9.54
Stock Dividends
Dividend 0
Forward Dividend 5.81e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android